{"entity":{"id":"nct07288177","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of Rinatabart sesutecan in non-small-cell lung cancer and small-cell lung cancer, run by Genmab, now recruiting.","summary":"Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT07288177 by Genmab, with 240 participants planned, started 2026-01-30 and due to reach its primary completion in 2027-11-22. Interventions recorded: Rina-S. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07288177","url":"https://clinicaltrials.gov/study/NCT07288177"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["rinatabart-sesutecan"],"companies":["genmab"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07288177","phase":"2","setting":"A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (Rina-S) in Participants With Non-Small Cell Lung Cancer","sponsor":"Genmab","enrolled":240,"outcomes":[]},"route":"/trials/nct07288177/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"rinatabart-sesutecan","kind":"drug","name":"Rinatabart sesutecan","route":"/drugs/rinatabart-sesutecan/"}],"company":[{"id":"genmab","kind":"company","name":"Genmab","route":"/companies/genmab/"}]}}